| an oncogene swap from EGFR to MET is a novel resistant mechanism to the EGFR-TKI. This novel mechanism should be considered in order to avoid futile inhibition of the original oncogene. | None |
| The alpha 2 chain of type 1 collagen does not map to mouse chromosome 16 but maps close to the Met proto-oncogene on mouse chromosome 6. | None |
| Absence of rearrangement of proto-oncogene MET in 88 cases of myelodysplastic syndromes (MDS). | None |
| Characterization of the mouse met proto-oncogene. | None |
| Proto-oncogene proteins c-met (MET) mutations Y1248H and D1246N confer resistance in vitro and in vivo. | None |
| Clarification of the chromosomal assignment of the human P-glycoprotein/mdr1 gene: possible coincidence with the cystic fibrosis and c-met oncogene. | None |
| findings show oncogene E5 is primarily responsible for Met upregulation; E5-induced Met contributes motility of HPV-containing cells; these studies show a new role for E5 in epithelial-stromal interactions, with implications for cancer development | None |
| NRP1 levels dictated the efficacy of MET oncogene inhibitors in addicted carcinoma cells. Mechanistically, NRP1 induced a JNK-dependent signaling cascade leading to the upregulation of alternative effector kinases. | None |
| Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. | None |
| Activation of the met proto-oncogene in a human cell line. | None |
| The met oncogene: a new member of the tyrosine kinase family and a marker for cystic fibrosis. | None |
| Properties of the met oncogene. | None |
| Chromosomal localization of the met proto-oncogene in the mouse and cat genome. | None |
| Activation of the met oncogene in the human MNNG-HOS cell line involves a chromosomal rearrangement. | None |
| The Met proto-oncogene mesenchymal to epithelial cell conversion. | None |
| Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. | None |
| Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus. | None |
| Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. | None |
| Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. | None |
| Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. | None |